Relapse of hepatitis C virus-associated mixed cryoglobulinemia vasculitis in patients with sustained viral response
- PMID: 18240235
- DOI: 10.1002/art.23305
Relapse of hepatitis C virus-associated mixed cryoglobulinemia vasculitis in patients with sustained viral response
Abstract
Objective: To investigate the clinical characteristics, outcomes, and results of hepatitis C virus (HCV) RNA analyses in a group of patients with HCV-associated mixed cryoglobulinemia (MC) vasculitis who experienced a relapse of vasculitis despite achieving a sustained viral response to treatment with antiviral agents.
Methods: HCV RNA testing was performed by the transcription-mediated amplification (TMA) method in sera and cryoprecipitates (detection limit 2.5 IU/ml). HCV replication was assessed in peripheral blood mononuclear cells (PBMCs) by a modified real-time polymerase chain reaction assay (detection limit 15 IU/10(6) cells).
Results: We identified 8 patients with relapse of HCV-MC vasculitis despite their having achieved a sustained viral response to treatment. Relapse appeared early after the end of treatment (mean +/- SD 2.5 +/- 3.5 months) and included mainly purpura (n = 7) and arthralgia (n = 5). Relapse was associated with an increase in serum cryoglobulin levels as compared with end-of-treatment levels (mean +/- SD 0.3 +/- 0.09 gm/liter and 0.08 +/- 0.04 gm/liter, respectively; P < 0.01) and a decrease in C4 levels. In most patients, the relapse was brief, and the MC vasculitis manifestations subsided. A search for HCV RNA by TMA was negative in all patients tested (7 of 8 patients), both in sera and in cryoprecipitates. HCV replication was not found in PBMCs from any of the patients tested (6 of 8 patients). In 3 patients, the MC vasculitis symptoms persisted and were associated with elevated cryoglobulin levels. B cell lymphoma was diagnosed in 2 of these 3 patients.
Conclusion: Relapse of MC vasculitis does occur in a few patients with HCV infection, despite achieving a sustained viral response, and this relapse is not related to persistence of virus. Relapse is short-lived and may be induced by the withdrawal of interferon alfa therapy. However, in patients with persistent MC vasculitis symptoms, a different underlying condition should be considered, especially B cell lymphoma.
Similar articles
-
Interferon-alpha and ribavirin treatment in patients with hepatitis C virus-related systemic vasculitis.Arthritis Rheum. 2002 Dec;46(12):3317-26. doi: 10.1002/art.10699. Arthritis Rheum. 2002. PMID: 12483738
-
Cryoglobulinaemia vasculitis in patients coinfected with HIV and hepatitis C virus.AIDS. 2006 Apr 4;20(6):871-7. doi: 10.1097/01.aids.0000218551.62210.b5. AIDS. 2006. PMID: 16549971
-
Longterm efficacy of interferon-alpha for extrahepatic disease associated with hepatitis C virus infection.J Rheumatol. 2001 Nov;28(11):2466-73. J Rheumatol. 2001. PMID: 11708420 Clinical Trial.
-
Hepatitis C-associated mixed cryoglobulinaemia: a crossroad between autoimmunity and lymphoproliferation.Rheumatology (Oxford). 2007 Aug;46(8):1234-42. doi: 10.1093/rheumatology/kem132. Epub 2007 Jun 12. Rheumatology (Oxford). 2007. PMID: 17566058 Review.
-
Treatment of autoimmune and extra-hepatic manifestations of HCV infection.Ann Med Interne (Paris). 2000 Feb;151(1):58-64. Ann Med Interne (Paris). 2000. PMID: 10761564 Review.
Cited by
-
Cryoglobulinemic Vasculitis Associated with Monoclonal Gammopathy of Undetermined Significance Developed after Sustained Virologic Response of Hepatitis C.Intern Med. 2023 Jul 1;62(13):1999-2004. doi: 10.2169/internalmedicine.9768-22. Epub 2022 Nov 16. Intern Med. 2023. PMID: 36384905 Free PMC article.
-
Persistent cryoglobulinemia after antiviral treatment is associated with advanced fibrosis in chronic hepatitis C patients.PLoS One. 2022 May 13;17(5):e0268180. doi: 10.1371/journal.pone.0268180. eCollection 2022. PLoS One. 2022. PMID: 35560166 Free PMC article.
-
Evolution of Cryoglobulinemia in Direct-Acting Antiviral-Treated Asian Hepatitis C Patients With Sustained Virological Responses: A 4-Year Prospective Cohort Study.Front Immunol. 2022 Mar 8;13:823160. doi: 10.3389/fimmu.2022.823160. eCollection 2022. Front Immunol. 2022. PMID: 35371039 Free PMC article.
-
Dynamics of serum α-fetoprotein in viral hepatitis C without hepatocellular carcinoma.Exp Ther Med. 2021 Jul;22(1):749. doi: 10.3892/etm.2021.10181. Epub 2021 May 12. Exp Ther Med. 2021. PMID: 34035846 Free PMC article.
-
Impact of Direct Acting Antiviral Agent Therapy upon Extrahepatic Manifestations of Hepatitis C Virus Infection.Curr HIV/AIDS Rep. 2019 Oct;16(5):389-394. doi: 10.1007/s11904-019-00466-1. Curr HIV/AIDS Rep. 2019. PMID: 31482299 Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous
